Ryoncil® is now available for purchase in the united states

New york, march 26, 2025 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that ryoncil® (remestemcel-l) the first mesenchymal stromal cell (msc) therapy approved by u.s. food and drug administration (fda) for any indication, is now available for purchase in the united states.
MESO Ratings Summary
MESO Quant Ranking